Amylin and amylin receptor agonists
Amylin and amylin receptor agonists groups 5 indexed compounds. Also written as amylin mimetics, amylin agonists, IAPP analogues.
Definition
This class groups the pancreatic hormone amylin, also called islet amyloid polypeptide, and the synthetic analogues modelled on it. A 2011 Physiological Reviews article covers islet amyloid polypeptide, islet amyloid and diabetes mellitus, a 1999 Molecular Pharmacology paper reports that multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product, and a 2021 Journal of Medicinal Chemistry paper reports the development of cagrilintide as a long-acting amylin analogue.
[1, 2, 3]Class-level mechanism as reported
The shared mechanism is agonism at amylin receptors, which the retrieved records describe as complexes of the calcitonin receptor with receptor activity-modifying proteins. A 2025 EBioMedicine paper reports that cagrilintide lowers bodyweight through brain amylin receptors 1 and 3 in its model, a 2001 Current Pharmaceutical Design paper frames pramlintide as amylin replacement, and a 2025 Lancet paper describes eloralintide as a selective amylin receptor agonist.
[2, 4, 5, 6]Members
| Compound | Other names | Peptide | Reported half-life |
|---|---|---|---|
| Cagrilintide | AM833, NNC0174-0833 | Yes | Withheld pending qualified review |
| Pramlintide | Symlin, pramlintide acetate | Yes | Withheld pending qualified review |
| Amylin | islet amyloid polypeptide, IAPP | Yes | Withheld pending qualified review |
| Petrelintide | ZP8396 | Yes | Withheld pending qualified review |
| Eloralintide | LY3841136 | Yes | Withheld pending qualified review |
5 of 5 compounds in this class are withheld pending qualified review, so their reported values are not shown here and their pages are not published. They are listed because the class is incomplete without them.
Where this page sits
Research records for compounds in this class
- Records indexed for Cagrilintide
- Records indexed for Pramlintide
- Records indexed for Amylin
- Records indexed for Petrelintide
- Records indexed for Eloralintide
All classes: class index. All compounds: compound index.
Sources
- Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiological reviews (2011). pmid:21742788
- Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Molecular pharmacology (1999). pmid:10385705
- Development of Cagrilintide, a Long-Acting Amylin Analogue. Journal of medicinal chemistry (2021). pmid:34288673
- Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. EBioMedicine (2025). pmid:40609154
- Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Current pharmaceutical design (2001). pmid:11472273
- Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet (London, England) (2025). pmid:41207310
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.